VEGFA and FLT1 targeted therapies are being explored as both pro- and anti-angiogenic therapies for several indications including retinal degeneration, cancer, pre-eclampsia, and neuromuscular diseases (Bae et al., 2005; Verma et al., 2010; Mac Gabhann et al., 2010; Keifer et al., 2014; Verma et al., 2019; Bosco et al., 2021; Xin et al., 2021). This evidence concerns the gene VEGFA and retinal degeneration.